CoChat

C-Reactive Protein: Higher During Acute Psychotic Episodes and Related to Cortical Thickness in Schizophrenia and Healthy Controls

Open access
Jacomb, Isabella, Stanton, Clive, Vasudevan, Rohini, Powell, Hugh, O'Donnell, Maryanne, Lenroot, Rhoshel, Bruggemann, Jason, Balzan, Ryan, Galletly, Cherrie, Liu, Dennis, Weickert, Cynthia S., Weickert, Thomas W. · 2018 · Frontiers in Immunology
Cited by 110

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

There is increasing evidence for the role of inflammation in schizophrenia, yet the stability of increased peripheral inflammation in acute psychosis and the degree to which peripheral inflammation relates to cortical thickness, a measure of the degree of neuropathology, are unknown. In independent samples, we assessed the peripheral inflammation marker C-reactive protein (CRP) to determine the extent to which: (1) CRP was elevated and stable across admissions for acute psychosis, (2) cognition, daily function and symptom severity are characteristic of chronically ill patients with schizophrenia displaying elevated CRP, and (3) CRP levels predict cortical thickness. Study 1 assessed peripheral CRP (primary outcome) and other blood measures in 174/280 people with acute psychosis while Study 2 assessed peripheral CRP, cognition and cortical thickness (primary outcomes), symptoms, and daily function in 85/97 chronically ill patients with schizophrenia and 71/87 healthy controls. In acute psychosis, CRP and neutrophil-to-lymphocyte ratio were significantly elevated relative to a normal cutoff (with 59.8% of patients having elevated CRP) which remained elevated across admissions. CRP was significantly elevated in 43% of chronically ill patients with schizophrenia compared to 20% in controls. Elevated CRP patients displayed significantly worse working memory and CRP was inversely correlated with cortical thickness in frontal, insula, and temporal brain regions. This work supports the role of inflammation in psychotic illnesses and suggests that use of peripheral markers (e.g., CRP) in conjunction with diagnosis could be used to identify patients with more cortical neuropathology and cognitive deficits.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2018.02230

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 64

  1. American, 2013, Diagnostic and Statistical Manual of Mental Disorders.
  2. Weickert, 2013, Biomarkers in schizophrenia: A brief conceptual consideration, Dis Markers, 35, 3, 10.1155/2013/510402 · DOI
  3. Weickert, 2016, What's hot in schizophrenia research?, Psychiatr Clin North Am, 39, 343, 10.1016/j.psc.2016.01.011 · DOI
  4. Gibney, 2013, Evidence for a dysregulated immune system in the etiology of psychiatric disorders, J Neuroimmune Pharmacol, 8, 900, 10.1007/s11481-013-9462-8 · DOI · Paper page
  5. Horvath, 2014, Immune system disturbances in schizophrenia, Biol Psychiatry, 75, 316, 10.1016/j.biopsych.2013.06.010 · DOI · Paper page
  6. Muller, 2014, Immunology of schizophrenia, Neuroimmunomodulation, 21, 109, 10.1159/000356538 · DOI · Paper page
  7. Benros, 2014, A nationwide study on the risk of autoimmune diseases in individuals with a personal or a family history of schizophrenia and related psychosis, Am J Psychiatry, 171, 218, 10.1176/appi.ajp.2013.13010086 · DOI · Paper page
  8. Chen, 2012, Prevalence of autoimmune diseases in in-patients with schizophrenia: nationwide population-based study, Br J Psychiatry, 200, 374, 10.1192/bjp.bp.111.092098 · DOI · Paper page
  9. Cazzullo, 2002, Cytokine profiles in schizophrenic patients treated with risperidone: a 3-month follow-up study, Prog Neuropsychopharmacol Biol Psychiatry, 26, 33, 10.1016/S0278-5846(01)00221-4 · DOI
  10. Zhang, 2004, Changes in serum interleukin-2,−6, and−8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia, J Clin Psychiatry, 65, 940, 10.4088/JCP.v65n0710 · DOI · Paper page
  11. Meyer, 2009, Inflammatory markers in schizophrenia: comparing antipsychotic effects in Phase 1 of the CATIE Schizophrenia Trial, Biol Psychiatry, 66, 1013, 10.1016/j.biopsych.2009.06.005 · DOI · Paper page
  12. Laan, 2010, Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial, J Clin Psychiatry, 71, 520, 10.4088/JCP.09m05117yel · DOI · Paper page
  13. Muller, 2002, Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia, Am J Psychiatry, 159, 1029, 10.1176/appi.ajp.159.6.1029 · DOI · Paper page
  14. Chaudhry, 2012, Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment, J Psychopharmacol, 26, 1185, 10.1177/0269881112444941 · DOI · Paper page
  15. Potvin, 2008, Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review, Biol Psychiatry, 63, 801, 10.1016/j.biopsych.2007.09.024 · DOI · Paper page
  16. Volk, 2015, Molecular mechanisms and timing of cortical immune activation in schizophrenia, Am J Psychiatry, 172, 1112, 10.1176/appi.ajp.2015.15010019 · DOI · Paper page
  17. Miller, 2013, Total and differential white blood cell counts, high-sensitivity C-reactive protien, and the metabolic syndrome in non-affective psychoses, Brain Behav Immun, 31, 82, 10.1016/j.bbi.2012.08.016 · DOI · Paper page
  18. Schott, 1996, Antinuclear antibodies in schizophrenia and major depressive disorder - A lasting puzzle, Eur Psychiatry, 11, 263, 10.1016/0924-9338(96)82334-0 · doi:10.1016/0924-9338(96)82334-0
  19. Spivak, 1995, Antinuclear autoantibodies in chronic schizophrenia, Acta Psychiatr Scand, 92, 266, 10.1111/j.1600-0447.1995.tb09581.x · DOI
  20. Kulaksizoglu, 2016, Relationship between neutrophil/lymphocyte ratio with oxidative stress and psychopathology in patients with schizophrenia, Neuropsychiatr Dis Treat, 12, 1999, 10.2147/NDT.S110484 · DOI · Paper page
  21. Semiz, 2014, Elevated neutrophil/lymphocyte ratio in patients with schizophrenia, Psychiatr Danub, 26, 220
  22. Singh, 2014, Role of C-reactive protein in schizophrenia: an overview, Psychiatry Res, 216, 277, 10.1016/j.psychres.2014.02.004 · DOI
  23. Zajkowska, 2014, First-episode psychosis: an inflammatory state?, Neuroimmunomodulation, 21, 102, 10.1159/000356536 · DOI · Paper page
  24. Deodhar, 1989, C-reactive protein: the best laboratory indicatory available for monitoring disease activity, Cleve Clin J Med, 56, 126, 10.3949/ccjm.56.2.126 · DOI · Paper page
  25. Libby, 2004, Inflammation and atherosclerosis: role of C-reactive protein in risk assessment, Am J Med, 116, 9, 10.1016/j.amjmed.2004.02.006 · DOI · Paper page
  26. Tsimikas, 2006, C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients, J Am Coll Cardiol, 47, C19, 10.1016/j.jacc.2005.10.066 · DOI · Paper page
  27. Miller, 2014, C-Reactive protein levels in schizophrenia: a review and meta-analysis, Clin Schizophr Relat Psychoses, 7, 223, 10.3371/CSRP.MICU.020813 · DOI · Paper page
  28. Metcalf, 2017, Serum C-reactive protein in adolescence and risk of schizophrenia in adulthood: a prospective birth cohort study, Brain Behav Immun, 59, 253, 10.1016/j.bbi.2016.09.008 · DOI · Paper page
  29. Bulzacka, 2016, Chronic peripheral inflammation is associated with cognitive impairment in schizophrenia: results from the multicentric FACE-SZ dataset, Schizophr Bull, 42, 1290, 10.1093/schbul/sbw029 · DOI · Paper page
  30. Dickerson, 2007, C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia, Schizophr Res, 93, 261, 10.1016/j.schres.2007.03.022 · DOI · Paper page
  31. Johnsen, 2016, The serum level of C-reactive protein (CRP) is associated with cognitive performance in acute phase psychosis, BMC Psychiatry, 16, 1, 10.1186/s12888-016-0769-x · DOI
  32. Fan, 2007, Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia, Psychiatry Res, 149, 267, 10.1016/j.psychres.2006.07.011 · DOI · Paper page
  33. Solanki, 2009, C-reactive protein (CRP) in patients with schizophrenia: are they related with symptomatology?, J Mental Health Hum Behav., 15, 6
  34. Mazzarello, 2004, Lymphocytes in schizophrenia patients under therapy: serological, morphological and cell subset findings, Ital J Anat Embryol, 109, 177
  35. Ohaeri, 1993, The profile of C-reactive proteins in functional psychotic states in a cohort in Nigeria, Acta Psychiatr Scand, 88, 252, 10.1111/j.1600-0447.1993.tb03452.x · doi:10.1111/j.1600-0447.1993.tb03452.x
  36. Bettcher, 2012, C-reactive protein is related to memory and medial temporal brain volume in older adults, Brain Behav Immun, 26, 103, 10.1016/j.bbi.2011.07.240 · DOI · Paper page
  37. Taki, 2013, Correlation between high-sensitivity C-reactive protein and brain gray matter volume in healthy elderly subjects, Hum Brain Mapp, 34, 2418, 10.1002/hbm.22073 · DOI
  38. Wing, 1998, Health of the Nation Outcome Scales (HoNOS), Br J Psychiatry, 172, 11, 10.1192/bjp.172.1.11 · DOI · Paper page
  39. Woods, 2003, Chlorpromazine equivalent doses for the newer atypical antipsychotics, J Clin Psychiatry, 64, 663, 10.4088/JCP.v64n0607 · DOI · Paper page
  40. Cohen, 1988, Statistical Power Analysis for the Behavioral Sciences.
  41. Shcherbakova, 1999, The possible role of plasma kallikrein-kinin system and leukocyte elastase in the pathogenesis of schizophrenia, Immunopharmacology, 43, 273, 10.1016/S0162-3109(99)00099-5 · DOI
  42. Barzilay, 2016, Elevated C-reactive protein in schizophrenia inpatients is associated with aggressive behavior, Eur Psychiatry, 31, 8, 10.1016/j.eurpsy.2015.09.461 · DOI · Paper page
  43. Raj, 2013, Antinuclear antibodies in general population: what does that mean?, J Immunol, 190, 197, 10.4049/jimmunol.190.Supp.197.2 · doi:10.4049/jimmunol.190.supp.197.2
  44. Yamada, 2001, Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population: jichi medical school cohort study, Am J Epidemiol, 153, 1183, 10.1093/aje/153.12.1183 · DOI · Paper page
  45. Costello, 2013, C-reactive protein and substance use disorders in adolescence and early adulthood: a prospective analysis, Drug Alcohol Depend, 133, 712, 10.1016/j.drugalcdep.2013.08.027 · DOI · Paper page
  46. O'Loughlin, 2008, Association between cigarette smoking and C-reactive protein in a representative, population-based sample of adolescents, Nicotine Tob Res, 10, 525, 10.1080/14622200801901997 · DOI · Paper page
  47. Weickert, 2015, Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia, Mol Psychiatry, 20, 685, 10.1038/mp.2015.11 · DOI
  48. First, 2002, Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition
  49. Wechsler, 1997, Wechsler Adult Intelligence Scale
  50. Wechsler, 2001, Wechsler Test of Adult Reading
  51. Lezak, 2004, Neuropsychological Assessment.
  52. Reitan, 1985, The Halstead-Reitan Neuropsychological Test Battery: Therapy and Clinical Interpretation
  53. Wechsler, 1987, Wechsler Memory Scale - Revised
  54. Kay, 1987, The positive and negative syndrome scale (PANSS) for schizophrenia, Schizophr Bull, 13, 261, 10.1093/schbul/13.2.261 · DOI · Paper page
  55. Ware, 2000, SF-36 Health Survey: Manual and Interpretation Guide
  56. Wilkinson, 2000, Self-report quality of life measure for people with schizophrenia: the SQLS, Br J Psychiatry, 177, 42, 10.1192/bjp.177.1.42 · DOI · Paper page
  57. Boerrigter, 2017, Using blood cytokine measures to define high inflammatory biotype of schizophrenia and schizoaffective disorder, J Neuroinflammation, 10.1186/s12974-017-0962-y · DOI · Paper page
  58. Callicott, 2003, Complexity of prefrontal cortical dysfunction in schizophrenia: more than up or down, Am J Psychiatry, 160, 2209, 10.1176/appi.ajp.160.12.2209 · DOI · Paper page
  59. Soufer, 1998, Cerebral cortical hyperactivation in response to mental stress in patients with cornary artery disease, Proc Natl Acad Sci USA, 95, 6454, 10.1073/pnas.95.11.6454 · DOI · Paper page
  60. Barbour, 2017, Vital signs: prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation - United States, 2013-2015, Morb Mortal Wkly Rep., 66, 246, 10.15585/mmwr.mm6609e1 · DOI · Paper page
  61. Gunstad, 2006, C-reactive protein, but not homocysteine, is related to cognitive dysfunction in older adults with cardiovascular disease, J Clin Neurosci, 13, 540, 10.1016/j.jocn.2005.08.010 · DOI
  62. Gozal, 2007, C-reactive protein, obstructive sleep apnea, and cognitive dysfunction in school-aged children, Am J Respir Crit Care Med, 176, 188, 10.1164/rccm.200610-1519OC · DOI · Paper page
  63. Trollor, 2010, Systemic inflammation is associated with MCI and its subtypes: the Sydney memory and aging study, Dement Geriatr Cogn Disord, 30, 569, 10.1159/000322092 · DOI · Paper page
  64. Mansur, 2012, Cytokines in schizophrenia: Possible role of anti-inflammatory medications in clinical and preclinical stages, Psychiatry Clin Neurosci, 66, 247, 10.1111/j.1440-1819.2012.02354.x · DOI

Cited by

See all 110

Metadata

Authors
Jacomb, I., Stanton, C., Vasudevan, R., Powell, H., O'Donnell, M., Lenroot, R., Bruggemann, J., Balzan, R., Galletly, C., Liu, D., Weickert, C. S., & Weickert, T. W.
Venue
Frontiers in Immunology
Published
2018-10-10
Volume
9
Pages
2230-2230
ISSN
1664-3224 (ISSN-L)
OpenAlex
W2896161650
Cited by
110
References
15
FWCI
1.89
Type
journal article
Language
en
Open access
gold
Funders
National Health and Medical Research Council (568807)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.